Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1988 Mar;71(3):486–492.

In vivo effects of C3a on neutrophils and its contribution to inflammatory lung processes in a guinea-pig model.

T Hoffmann 1, E C Böttger 1, H P Baum 1, M Messner 1, U Hadding 1, D Bitter-Suermann 1
PMCID: PMC1541683  PMID: 3260158

Abstract

C3a, when injected intravenously in guinea-pigs, caused a rapid drop of circulating neutrophils and platelets. The neutropenia was reversible and followed by a neutrophilia, which reached about 200% of baseline values. Upon challenge with octa- and hexapeptide, mimicking the C-terminal sequence of C3a, neutrophils and platelets reacted in the same manner. The hexapeptide-desArg (pentapeptide without the C-terminal arginine of hexapeptide) induced no neutropenia but a significant neutrophilia. Likewise, when injected in animals with a genetic deficiency or dysfunction of the C3a-receptor, the hexapeptide caused no drop of the neutrophils, but a neutrophilia, indicating that both neutrophil reactions are mediated by different mechanisms. With the octapeptide in vivo dose-response studies were performed. Despite maximal doses of octapeptide about 40% of the neutrophils remained in circulation, indicating that some but not all PMNs are susceptible to C3a. By pretreating the animals with an inhibitor of the serum carboxypeptidase N (SCPN-Inh) the C3a-induced neutropenia could be significantly augmented. But intravenous application of the inhibitor itself caused a 20-40% reduction of neutrophils during the first hour after injection, followed by a neutrophilia. In histological studies the timecourse of neutrophil sequestration in the lung was established, showing that the initial high neutrophil content of the lung lasted for at least 1 h and declined thereafter. Structural derangements could not be detected. These observations stress the importance of C3a besides C5a as an important mediator of inflammatory processes in species, where the C3a-receptor is present on inflammatory cells such as granulocytes.

Full text

PDF
486

Images in this article

487Fig. 1
on p.487
490Fig. 4
on p.490

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Becker S., Hadding U., Schorlemmer H. U., Bitter-Suermann D. Demonstration of high-affinity binding sites for C3a anaphylatoxin on guinea-pig platelets. Scand J Immunol. 1978;8(6):551–555. doi: 10.1111/j.1365-3083.1978.tb00555.x. [DOI] [PubMed] [Google Scholar]
  2. Bitter-Suermann D., Becker S., Meuer S., Schorlemmer H. U., Hadding U., Andreatta R. Comparative study on biological effects of the guinea pig complement-peptide C3a and C3a-related synthetic oligopeptides. Mol Immunol. 1980 Oct;17(10):1257–1261. doi: 10.1016/0161-5890(80)90022-x. [DOI] [PubMed] [Google Scholar]
  3. Bitter-Suermann D., Burger R. Guinea pigs deficient in C2, C4, C3 or the C3a receptor. Prog Allergy. 1986;39:134–158. [PubMed] [Google Scholar]
  4. Craddock P. R., Fehr J., Dalmasso A. P., Brighan K. L., Jacob H. S. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest. 1977 May;59(5):879–888. doi: 10.1172/JCI108710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Craddock P. R., Hammerschmidt D. E., Moldow C. F., Yamada O., Jacob H. S. Granulocyte aggregation as a manifestation of membrane interactions with complement: possible role in leukocyte margination, microvascular occlusion, and endothelial damage. Semin Hematol. 1979 Apr;16(2):140–147. [PubMed] [Google Scholar]
  6. Damerau B., Grünefeld E., Vogt W. Aggregation of leukocytes induced by the complement-derived peptides C3a and C5a and by three synthetic formyl-methionyl peptides. Int Arch Allergy Appl Immunol. 1980;63(2):159–169. doi: 10.1159/000232622. [DOI] [PubMed] [Google Scholar]
  7. Damerau B., Höllerhage H. G., Vogt W. Effects of the cleavage peptides, C3q and C3ai, from the third component of hog complement on leukocyte accumulation and vascular permeability in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1978 Mar;302(1):45–50. doi: 10.1007/BF00586595. [DOI] [PubMed] [Google Scholar]
  8. Daniele R. P., Henson P. M., Fantone J. C., 3rd, Ward P. A., Dreisin R. B. Immune complex injury of the lung. Symposium held at the 74th annual meeting of the American Thoracic Society, Las Vegas, Nevada, May 1979. Am Rev Respir Dis. 1981 Dec;124(6):738–755. [PubMed] [Google Scholar]
  9. Fernandez H. N., Henson P. M., Otani A., Hugli T. E. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol. 1978 Jan;120(1):109–115. [PubMed] [Google Scholar]
  10. Glovsky M. M., Hugli T. E., Ishizaka T., Lichtenstein L. M., Erickson B. W. Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release. J Clin Invest. 1979 Sep;64(3):804–811. doi: 10.1172/JCI109527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gorski J. P., Hugli T. E., Müller-Eberhard H. J. C4a: the third anaphylatoxin of the human complement system. Proc Natl Acad Sci U S A. 1979 Oct;76(10):5299–5302. doi: 10.1073/pnas.76.10.5299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hammerschmidt D. E., Weaver L. J., Hudson L. D., Craddock P. R., Jacob H. S. Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value. Lancet. 1980 May 3;1(8175):947–949. doi: 10.1016/s0140-6736(80)91403-8. [DOI] [PubMed] [Google Scholar]
  13. Henson P. M., McCarthy K., Larsen G. L., Webster R. O., Giclas P. C., Dreisin R. B., King T. E., Shaw J. O. Complement fragments, alveolar macrophages, and alveolitis. Am J Pathol. 1979 Oct;97(1):93–110. [PMC free article] [PubMed] [Google Scholar]
  14. Hoffmann T., Böttger E. C., Baum H. P., Dennebaum R., Hadding U., Bitter-Suermann D. Evaluation of low dose anaphylatoxic peptides in the pathogenesis of the adult respiratory distress syndrome (ARDS). Monitoring of early C5a effects in a guinea-pig in vivo model after i.v. application. Eur J Clin Invest. 1986 Dec;16(6):500–508. doi: 10.1111/j.1365-2362.1986.tb02168.x. [DOI] [PubMed] [Google Scholar]
  15. Hosea S., Brown E., Hammer C., Frank M. Role of complement activation in a model of adult respiratory distress syndrome. J Clin Invest. 1980 Aug;66(2):375–382. doi: 10.1172/JCI109866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Huey R., Bloor C. M., Kawahara M. S., Hugli T. E. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue. Am J Pathol. 1983 Jul;112(1):48–60. [PMC free article] [PubMed] [Google Scholar]
  17. Larsen G. L., McCarthy K., Webster R. O., Henson J., Henson P. M. A differential effect of C5a and C5a des Arg in the induction of pulmonary inflammation. Am J Pathol. 1980 Jul;100(1):179–192. [PMC free article] [PubMed] [Google Scholar]
  18. McCall C. E., De Chatelet L. R., Brown D., Lachmann P. New biological activity following intravascular activation of the complement cascade. Nature. 1974 Jun 28;249(460):841–843. doi: 10.1038/249841a0. [DOI] [PubMed] [Google Scholar]
  19. Meuer S., Becker S., Hadding U., Bitter-Suermann D. The anaphylatoxic peptide C3a of guinea pig complement. I. Purification, physicochemical and antigenetic properties. Z Immunitatsforsch Immunobiol. 1978 Mar;154(2):135–146. [PubMed] [Google Scholar]
  20. Meuer S., Ecker U., Hadding U., Bitter-Suermann D. Platelet-serotonin release by C3a and C5a: two independent pathways of activation. J Immunol. 1981 Apr;126(4):1506–1509. [PubMed] [Google Scholar]
  21. Meuer S., Hugli T. E., Andreatta R. H., Hadding U., Bitter-Suermann D. Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a). Investigations on their ability to induce platelet secretion. Inflammation. 1981 Dec;5(4):263–273. doi: 10.1007/BF00911092. [DOI] [PubMed] [Google Scholar]
  22. Polley M. J., Nachman R. L. Human platelet activation by C3a and C3a des-arg. J Exp Med. 1983 Aug 1;158(2):603–615. doi: 10.1084/jem.158.2.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rinaldo J. E., Rogers R. M. Adult respiratory-distress syndrome: changing concepts of lung injury and repair. N Engl J Med. 1982 Apr 15;306(15):900–909. doi: 10.1056/NEJM198204153061504. [DOI] [PubMed] [Google Scholar]
  24. Showell H. J., Glovsky M. M., Ward P. A. C3a-induced lysosomal enzyme secretion from human neutrophils: lack of inhibition by f met-leu-phe antagonists and inhibition by arachidonic acid antagonists. Int Arch Allergy Appl Immunol. 1982;67(3):227–232. doi: 10.1159/000233023. [DOI] [PubMed] [Google Scholar]
  25. Stimler N. P., Hugli T. E., Bloor C. M. Pulmonary injury induced by C3a and C5a anaphylatoxins. Am J Pathol. 1980 Aug;100(2):327–348. [PMC free article] [PubMed] [Google Scholar]
  26. Webster R. O., Larsen G. L., Mitchell B. C., Goins A. J., Henson P. M. Absence of inflammatory lung injury in rabbits challenged intravascularly with complement-derived chemotactic factors. Am Rev Respir Dis. 1982 Mar;125(3):335–340. doi: 10.1164/arrd.1982.125.3.335. [DOI] [PubMed] [Google Scholar]
  27. van Epps D. E., Chenoweth D. E. Analysis of the binding of fluorescent C5a and C3a to human peripheral blood leukocytes. J Immunol. 1984 Jun;132(6):2862–2867. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES